Evidence map›Paper›PMID 27492370›Full record

ReviewCurrent hypertension reports2016

Relationship Between Antihypertensive Medications and Cognitive Impairment: Part I. Review of Human Studies and Clinical Trials.

Sevil Yasar, Mattan Schuchman, Jean Peters, Kaarin J Anstey, Michelle C Carlson, Ruth Peters

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current hypertension reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Longitudinal relation between blood pressure, antihypertensive use and cerebral blood flow, using arterial spin labelling MRI.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Article
  9. Review
  10. Article
  11. Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sevil YasarDivision of Geriatric Medicine and Gerontology, Department of Medicine, Baltimore, Johns Hopkins School of Medicine, Baltimore, MD, 21224, USA.
Mattan SchuchmanDivision of Geriatric Medicine and Gerontology, Department of Medicine, Baltimore, Johns Hopkins School of Medicine, Baltimore, MD, 21224, USA.
Jean PetersSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
Kaarin J AnsteyCentre for Research on Ageing, Health and Wellbeing, College of Medicine, Biology and Environment Australian National University, Canberra, Australia.
Michelle C CarlsonDepartment of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21224, USA.
Ruth PetersSchool of Public Health, Imperial College London, London, SW7 2AZ, UK. r.peters@imperial.ac.uk.

Funding

'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI ALBERT, MARILYN S. · 1985 to 2019
$37.6M
Department of Health PDF-2012-05-197NIA NIH HHS P50 AG005146
6 · The paper itself

Abstract

purpose of reviewThere is an established association between hypertension and increased risk of poor cognitive performance and dementia including Alzheimer's disease; however, associations between antihypertensive medications (AHMs) and dementia risk are less consistent. An increased interest in AHM has resulted in expanding publications; however, none of the recent reviews are comprehensive. Our extensive review includes 15 observational and randomized controlled trials (RCTs) published over the last 5 years, assessing the relationship between AHM and cognitive impairment. RECENT

findingsAll classes of AHM showed similar result patterns in human studies with the majority of study results reporting point estimates below one and only a small number of studies (N = 15) reporting statistically significant results in favor of a specific class. Only a small number of studies reported statistically significant results in favor of a specific class of AHM. Methodological limitations of the studies prevent definitive conclusions. Further work is now needed to evaluate the class of AHM and cognitive outcomes in future RCTs, with a particular focus on the drugs with the promising results in both animals and human observational studies.

Indexed as

Alzheimer DiseaseAntihypertensive AgentsCognitive DysfunctionHumansHypertensionObservational Studies as TopicRandomized Controlled Trials as TopicRisk FactorsStatistics as TopicAntihypertensive AgentsAlzheimer’s diseaseAntihypertensive medicationCognitive declineDementia

Identifiers

PMID27492370
PMCPMC4975763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.